BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric ...

A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...

Please provide your email address to receive an email when new articles are posted on . Once-daily linaclotide improved weekly spontaneous bowel movements from 1.16 to 3.41 during the 12-week ...

There are no known causes and usually multiple factors leading to the common condition that makes stools hard and difficult to pass, according to the FDA. Linzess was approved in 2012 for adult ...

– Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years with functional constipation – Functional constipation in children is defined as a ...

Constipation in children is increasing. To prevent long-term gut issues, parents need to act early and identify constipation symptoms.

– Data demonstrates that linaclotide reduces the need for rescue medications in this patient population – – Additional presentations further characterize the efficacy and safety profiles of ...